- skin cancer
- general dermatology
Dr Louise Fearfield has both a private and an NHS practice at The Royal Marsden. She is a Consultant Dermatologist with an interest in skin cancer and cutaneous oncology at The Royal Marsden and Chelsea and Westminster Hospitals.
She did her medical training at Oriel College Oxford and St Thomas’ Hospital London, qualifying as a doctor in 1992. Her first dermatology training post was at Chelsea and Westminster Hospital and The Royal Marsden, which she started in 1995. During this time she developed her interest in skin cancer and took two years out to complete her DM thesis on prognostic factors in melanoma, which was awarded in 2002 at Oxford University.
She was initially appointed as a Consultant Dermatologist at the Royal Berkshire Hospital and Honorary Consultant at The Royal Marsden in 2002, leaving in 2010. During this time she set up the local skin cancer service, chaired the skin cancer multidisciplinary clinic and recruited the first skin cancer nurse specialist for the region. In 2009 she successfully completed the first peer review for skin cancer for the network and local region. During this time and was also chair of the Thames Valley Cancer Network for skin cancer and was involved in strategic planning for skin cancer and development of services and guidelines for treatment.
Her present appointment involved developing the rapid diagnostic service for skin diseases in The Royal Marsden’s Rapid Diagnostic and Assessment Centre. She was chair of the specialist multidisciplinary team skin cancer team at the Chelsea and Westminster up until 2019. In 2018 she was elected into a national role as Clinical Vice President of the British Association of Dermatology. This has involved developing NICE accredited service standards for dermatology, working closely with the CQC and developing the recently published brief guide to dermatology services to enable CQC inspectors to review dermatology departments, working closely with trusts across the UK that need support and organising the British Association of Dermatology annual centenary meeting in July 2020.
Her initial research interests involved looking at prognostic factors in primary melanoma. However, since her appointment to The Royal Marsden she has also developed a research interest in the cutaneous toxicities associated with the newer targeted therapies and checkpoint inhibitors used in the treatment of metastatic malignant melanoma as well as other cancers. She has been invited to national and international meeting as a plenary speaker presenting on this work and has published many articles in peer reviewed journals